ScheBo^® • Tumor M2-PK™ Stool Test

Colorectal (bowel) cancer is one of the most common cancers in the western world, affecting around 160 000 people annually in the USA and 370 000 in Europe and resulting in about 55 000 and 200 000 deaths per annum respectively. If diagnosed early, the chances of a cure are very high (nearly 100%).

The most reliable investigation for diagnosis of colorectal cancer is total colonoscopy. However, the acceptance of this costly and invasive method is low. For a succesful colorectal cancer screening program it is therefore necessary to use the next best screening tools, which should be easy, economical and most of all be well accepted by patients. Patients identified by these tools should be investigated further by colonoscopy.

The currently most commonly used test for bowel cancer screening is the Faecal Occult Blood Test (FOBT). As it simply recognises blood in the stool the test is non-specific for colorectal cancer. Hence the interpretation of the result can be very difficult and inexact. In addition, only bleeding colorectal tumors - if any - are recognised. The largest study conducted so far on this subject is the American Veterans Association study in which a total of 2885 participants underwent total colonoscopy. The result was that only 23,9% of those participants with advanced neoplasia had a positive faecal occult blood test.

The ScheBo^® • Tumor M2-PK™ Stool Test is a totally new approach, which is much more sensitive than previous laboratory bowel cancer screening tests. Previously, only non-specific tests for blood in the stool could be used to give an indication of an existing bowel cancer or its precursors. With the new ELISA method for Tumor M2-PK in the stool it′s now possible to detect bleeding or non-bleeding bowel cancers, as well as polyps, with high sensitivity and specificity. The test is more accurate because it is not dependent on occult blood.

The main advantages of the ScheBo^® • Tumor M2-PK^® Stool Test are:

• High sensitivity
• High specificity
• Not dependent on occult blood
• Detects bleeding or non-bleeding bowel polyps, especially >1cm
• Detects bleeding or non-bleeding bowel tumours
• Not affected by specific foods
• No special diet required
• No false results from haemorrhoids or other sources of blood in the bowel
• A single pea-sized sample is sufficient

The ScheBo^® • Tumor M2-PK^® Stool Test detects about 85% of all tumors with single testing . This is much better than only 30% at most with the faecal occult blood test.

Even polyps are detected:

• » ELISA-test, laboratory
  The metabolic biomarker "Faecal Tumor M2-PK" is a screening parameter for colorectal (bowel) cancer and polyps and is independent of "Faecal Occult Blood" (FOB).
  
  
• » Rapid test
  Rapid Test for detecting colorectal and other gastrointestinal tumors for all medical services